Product Name: Ret (177-191)
Product Number: PE-01AVA99
Size: 200 µg      Price:51.00
1 mg      $US102.00
5 mg      224.00
Peptide Name: Ret (177-191)

Product Use: Services as a blocking peptide for use with the Ret-1 rabbit polyclonal antibody (Cat. No.: AB-NK244-1) that is also available from Kinexus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CRENRPPGTFHQFRLL

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1970.3 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Ret pan-specific antibody (Cat. No.: AB-NK244-1)

Scientific Background: Ret is a receptor protein-tyrosine in the TK group of protein kinases in the Ret family. It is highly expressed and widely distributed in most tested human tissues. Ret is activated by binding one of four structurally ligands (i.e. GDNF, neurturin, artemin and persephin). Autophosphorylation of S696, Y806, Y809, Y864, Y900, Y905, Y928, Y952, Y981 and Y1062 of Ret increases its phosphotransferase activity. Phosphorylation of Y1015 inhibits its phosphotransferase activity. Protein interactions are induced with phosphorylation of Y981 (with Src), Y1062 (with Crk, Dok6, FRS2, Gab1, IRS1, PIK3R1, RapGEF1, Shc1 & Shc3), and Y1096 (with Grb2 & PIK3R1). Phosphorylation of Y1015 inhibits kinase activity. Ret orchestrates intestine organogenesis. Germline mutations of Ret cause a dominantly inherited dysgenesis of the enteric nervous system known as Hirschsprung's disease. Ret can undergo oncogenic activation by cytogenetic rearrangement. It is constitutively activated by point mutations in hereditary medullary thyroid carcinomas (MTCs). Multiple endocrine neoplasia type 2A (MEN 2A) is associated with two mutations of Ret. It was identified as a potential low-penetrance gene for apparently sporadic pheochromocytoma. Ret has also been linked with congenital central hypoventilation syndrome, bladder carcinomas, and colorectal adenocarcinomas.